Cogent Biosciences, Inc. (COGT) Earnings History
Annual and quarterly earnings data from 2015 to 2025
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
Download Data
Export COGT earnings history in CSV or JSON format
Free sign-in required to download data
Cogent Biosciences, Inc. (COGT) Earnings Overview
As of February 28, 2026, Cogent Biosciences, Inc. (COGT) reported trailing twelve-month net income of -$329M, reflecting -0.0% year-over-year growth. The company earned $-4.87 per diluted share over the past four quarters.
Looking at the long-term picture, COGT's historical earnings data spans multiple years. The company achieved its highest annual net income of -$7M in fiscal 2015.
Cogent Biosciences, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to industry peers including AGIO (-$401M net income, -7.6% margin), VRTX ($3.68B net income, 0.3% margin), ASND (-$228M net income, -0.3% margin), COGT has comparable earnings metrics. Compare COGT vs AGIO →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
11 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$329M | -28.6% | -$333M | $-2.55 | - | - |
| 2024 | -$256M | -33.0% | -$276M | $-2.46 | - | - |
| 2023 | -$192M | -37.2% | -$208M | $-2.42 | - | - |
| 2022 | -$140M | -94.0% | -$148M | $-2.26 | - | - |
| 2021 | -$72M | +3.4% | -$76M | $-1.85 | - | - |
| 2020 | -$75M | -147.1% | -$82M | $-6.00 | -950.4% | -1044.3% |
| 2019 | -$30M | +12.3% | -$32M | $-3.97 | -134.6% | -143.0% |
| 2018 | -$35M | -35.5% | -$36M | $-5.55 | -354.8% | -369.9% |
| 2017 | -$25M | -40.7% | -$26M | $-3.45 | -304.9% | -312.8% |
| 2016 | -$18M | -174.9% | -$19M | $-2.45 | -285.2% | -300.1% |
See COGT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs COGT Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare COGT vs AGIO
See how COGT stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is COGT growing earnings?
COGT TTM EPS: $-4.87. Net income: $-329M. Earnings growth: -0.0%.
What are COGT's profit margins?
Cogent Biosciences, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are COGT's earnings?
COGT earnings data spans 2015-2025. The current earnings trend is -0.0% YoY. Historical data enables comparison across business cycles.